These 4 charts show the scale of Novo Nordisk’s woes
[ad_1] Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe’s most valuable company. But its troubles are stacking up and today the stock trades at just a quarter of what it did at its peak less than two years ago. Pricing pressure, fierce competition, and pipeline setbacks […]
Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades
[ad_1] Analysts added to the sour mood around Novo Nordisk , racing to cut price targets on the stock, after the Danish drugmaker published disappointing trial results on what it hoped to be its next big weight loss drug. The drug, CagriSema didn’t meet the key goal of matching rival medicine Zepbound, developed by Eli […]
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly’s in trial
[ad_1] Novo Nordisk stock fell over 10% Monday after it said its next-generation weight loss drug didn’t meet its primary target. The drug, CagriSema, didn’t achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly‘s rival drug tirzepatide after 84 weeks, Novo said in a statement Monday morning. Eli Lilly‘s […]
Novo Nordisk CEO sees 15 million patient opportunity in Medicare coverage for obesity drugs
[ad_1] Novo Nordisk CEO Mike Doustdar on Wednesday said the company is aiming to capture around 15 million new patients, at least initially, when Medicare starts covering obesity treatments for the first time later this year. Around 67 million Americans are covered by Medicare, but “when you take a look at specifically our products and […]